Bavarian Nordic (United States)

Recent papers from Bavarian Nordic (United States)

1. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trialThe Lancet · 2025
2. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trialThe Lancet · 2025
3. Ammonite biostratigraphy of the Aalenian and Lower Bajocian (Middle Jurassic) near Böttstein (Canton Aargau, Northern Switzerland)Zitteliana · 2026
4. Expert Recommendations to Strengthen Chikungunya Outbreak Surveillance and Reporting for Traveler Health ProtectionAmerican Journal of Tropical Medicine and Hygiene · 2026
5. Alternative approaches to phase III clinical trials for vaccine efficacy and licensure: the role of real-world evidence – a meeting reportBiologicals · 2026
6. Chikungunya virus virus-like particle vaccine (Vimkunya) induces a rapid and durable antigen-specific CD4+ T cell responseVaccine · 2026
7. A chikungunya virus-like particle vaccine reduces chikungunya disease in cynomolgus macaques and protection is mediated by antibody transferred from vaccinated humansnpj Vaccines · 2026
8. Drelów, the 13th and latest meteorite fall in Poland—A typical L6 chondrite with shock veinsMeteoritics and Planetary Science · 2026
9. MVA-Spike encoding the A subunit of dmLT safely enhances systemic and mucosal immune responsesSHILAP Revista de lepidopterología · 2026
10. Ecological drivers of chikungunya virus transmission: baseline results from a geographically structured, longitudinal study in southern Thailand2026
11. Passive transfer of human sera from chikungunya virus virus-like particle vaccine (Vimkunya) recipients fully protects non-human primates from viremianpj Vaccines · 2026
12. Mpox: Exploring Epidemiology, Disease Outcomes, and Preventative Vaccination Among People with HIV During the Ongoing OutbreaksViruses · 2025
13. Post-authorisation experience and reported adverse events following use of a virus-like particle chikungunya vaccine, United States and Germany, up to August 2025Eurosurveillance · 2025
14. Genomic prediction in a small barley population can benefit from training on related populationsG3 Genes Genomes Genetics · 2025
15. Public Health Impact of the MVA-BN Vaccine During the 2022 Mpox Outbreak: A Systematic ReviewInfectious Disease Reports · 2025
16. Predictability of infectious disease outbreak severity: Chikungunya as a case studyScience Advances · 2025
17. ‘Diving deeper’: affordances and constraints for infusing critical inquiry into language educationCritical Inquiry in Language Studies · 2025
18. Virus-like particles: a versatile and effective vaccine platformExpert Review of Vaccines · 2025
19. Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled studyThe Lancet Microbe · 2025
20. Contactless body temperature assessment for signalling humane endpoints in a mouse model of sepsisAnimal Welfare · 2025